Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects

References

• Dax SL. Antibacterial Chemotherapeutic Agents. London: Blackie Academic & Professional, 1997:298–345.
   Google Scholar
• Lee C, Ronald AR. Norfloxacin: its potential in clinical practice. Am J Med 1987;82:27–34.
   PubMed Web of Science ®Google Scholar
• Patrick GL. An Introduction to Medicinal Chemistry. Oxford: Oxford University Press, 2003:379–435.
   Google Scholar
• Buck ML. Ciprofloxacin use in children: a review of recent findings. Pediatr Pharm 1998;4:12–18.
   Google Scholar
• Pandey SN. A Text Book of Medicinal Chemistry (Synthetic and Biochemical Approach). Bhelpur: Mahavir Press, 2003:547–85.
   Google Scholar
• Torriero AAJ, Ruiz-Diaz JJJ, Salinas E, Marchevsky EJ, Sanz MI, Raba J. Enzymatic rotating biosensor for ciprofloxacin determination. Talanta 2006;69:691–9.
   PubMed Web of Science ®Google Scholar
• Guneysel O, Onur O, Erdede M, Dehizbasi A. Trimetoprim/sulfamethoxazole resistance in urinary tract infections. J Emerg Med 2009;36:338–41.
   PubMed Web of Science ®Google Scholar
• Karachalios GN, Zografos G, Patrikakos V, Nassopoulou D, Kehagioglou K. Biliary tract infections treated with ciprofloxacin. Infection 2005;21:262–4.
   Web of Science ®Google Scholar
• Abraham DJ. Burger’s Medicinal Chemistry Drug Discovery. Hoboken, NJ: John Wiley & Sons, 2003:582–7.
   Google Scholar
• Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000;16:5–15.
   PubMed Web of Science ®Google Scholar
• De Almeida MV, Saraiva MF, De Souza MVN, Da Costa CF, Vincente FRC, Lourenco MCS. Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives. Bioorg Med Chem Lett 2007;17:5661–4.
   PubMed Web of Science ®Google Scholar
• Cooper JG, Harboe K, Frost SK, Skadberg O. Ciprofloxacin interacts with thyroid replacement therapy. BMJ 2005;330:1002.
   PubMed Web of Science ®Google Scholar
• Ciprofloxacin. http://en.wikipedia.org/w/index.php?title=Ciprofloxacin&oldid=287777716. Accessed 6 May 2009.
   Google Scholar
• Cipro. Bayer response 12 Feb 2009. http://www.fda.gov/cder/foi/label/2009/019537s69,19847s43,19857s50,20780s27lbl.pdf. Accessed 6 May 2009.
   Google Scholar
• Anquetin G, Greiner J, Mahmoud N, Santillana HM, Gozalbes R, Farhati K, et al. Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones. Eur J Med Chem 2006;41:1478–93.
   PubMed Web of Science ®Google Scholar
• Farhi D, Dupin N. The rise of fluoroquinolone-resistant Neisseria gonorrhoeae. Swiss Med Wkly 2008;138:223–4.
   PubMed Web of Science ®Google Scholar
• Brunner M, Langer O, Dobrozemsky G, Muller U, Zeitlinger M, Mitterhauser M, et al. [18F] Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. Antimicrob Agents Chemother 2004;48:3850–7.
   PubMed Web of Science ®Google Scholar
• Kubin R. Safety and efficacy of ciprofloxacin in paedatric patients—review. Infection 1993;21:413–21.
   PubMed Web of Science ®Google Scholar
• Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther 1998;20:1049–68.
   PubMed Web of Science ®Google Scholar
• Antonio DD, Piccolomini R, Iacone A, Fioritoni G, Parruti G, Betti S, et al. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1994;33:837–44.
   PubMed Web of Science ®Google Scholar
• Yamane N, Jones RN, Frei R, Hoban DJ, Pignatari AC, Marco F. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J Chemother 1994;6:83–91.
   PubMed Web of Science ®Google Scholar
• Joseph E, Dohar MD, Wall M, Peter S, Roland PS, Dupre SJ, et al. Topical ciprofloxacin/dexamethasone found superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea. Otolaryngol Head Neck Surg 2005;133:127.
   Google Scholar
• Brunner H, Zeiler HJ. Oral ciprofloxacin treatment for salmonella typhimurium infection of normal and immunocompromised mice. Antimicrob Agents Chemother 1988;32:57–62.
   PubMed Web of Science ®Google Scholar
• Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002;86:443–8.
   PubMed Web of Science ®Google Scholar
• Aranha O, Wood DP, Sarkar FH. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 2000;6:891–900.
   PubMed Web of Science ®Google Scholar
• Aranha O, Grignon R, Fernandes N, Mcdonnell TJ, Wood DP, Sarkar FH. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 2003;22:787–94.
   PubMed Web of Science ®Google Scholar
• Pinto AC, Moreira JN, Simoes S. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol 2009;64:445–54.
   PubMed Web of Science ®Google Scholar
• Bourikas LA, Kolios G, Valatas V, Notas G, Drygiannakis I, Pelagiadis I, et al. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol 2009;157:362–70.
   PubMed Web of Science ®Google Scholar
• Ibukun EA, Eyitayo OA, Nwaka DUC, Aminat OA, Aderemi TA, Oludare FA, et al. Emergence of cross-resistance to fluoroquinolones in Gram-negative isolates from cancer infections in a tertiary hospital in Nigeria. J Am Sci 2008;4:14–20.
   Google Scholar
• Dekker AW, Rosenberg AM, Verhoef J. Infection prophylaxis in acute leukaemia: a comparison of ciprofloxacin with trimethoprim–sulfamethoxazole and colistin. Anna Intern Med 1987;106:7–11.
   PubMed Web of Science ®Google Scholar
• Haron E, Rolston KVI, Cunningham C, Holmes F, Umsawasdi T, Bodey GP. Oral ciprofloxacin therapy for infections in cancer patients. J Antimicrob Chemother 1989;24:955–62.
   PubMed Web of Science ®Google Scholar
• Balkhy HH, Memish ZA, Shibl A, Elbashier A, Osoba A. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia. East Mediterr Health J 2005;11:36–44.
   PubMedGoogle Scholar
• Aydemir S, Tunger A, Cilli F. In vitro activity of fluoroquinolones against common respiratory pathogens. West Indian Med J 2006;55:9–12.
   PubMed Web of Science ®Google Scholar
• Cassell GH, Mekalanos J. Development of antimicrobial agent in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA 2001;285:601–5.
   PubMed Web of Science ®Google Scholar
• Rubin J, Walker RD, Blickenstaff K, Jones SB, Zhao S. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. Vet Microbiol 2008;131:164–72.
   PubMed Web of Science ®Google Scholar
• Cozzarelli NR. DNA gyrase and the supercoiling of DNA. Science 1980;207:953–60.
   PubMed Web of Science ®Google Scholar
• Schmidt FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998;41:481–4.
   PubMed Web of Science ®Google Scholar
• Walters JD, Zhang F, Nakkula RJ. Mechanism of fluoroquinolone transport by human neutrophils. Antimicrob Agents Chemother 1999;43:2710–15.
   PubMed Web of Science ®Google Scholar
• Shaharyar M, Ashraf Ali EM, Abdullah MM. Synthesis and antiproliferative activity of 1-[(sub)]-6-fluoro-3-[(sub)]-1,3,4-oxadiazol-2-yl-7-piperazino-1,4-dihydro-4-quinolone derivatives. Med Chem Res 2007;16:292–9.
   Web of Science ®Google Scholar
• Vila J, Sanchez-Cespedes J, Sierra JM, Piqueras M, Nicolas E, Freixas J, et al. Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria. Int J Antimicrob Agents 2006;28:19–24.
   PubMed Web of Science ®Google Scholar
• Foroumadi A, Emami S, Mehni M, Moshafi MH, Shafiee A. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[2-(5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones. Bioorg Med Chem Lett 2005;15:4536–9.
   PubMed Web of Science ®Google Scholar
• Foroumadi A, Emami S, Hassanzadeh A, Rajaee M, Sokhanvar K, Moshafi MH, et al. Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)piperazinyl quinolone derivatives. Bioorg Med Chem Lett 2005;15:4488–92.
   PubMed Web of Science ®Google Scholar
• Foroumadi A, Oboudiat M, Emami S, Karimollah A, Saghaee L, Moshafi MH, et al. Synthesis and antibacterial activity of N-[2-[5-(methylthio)thiophen-2-yl]-2-oxoethyl] and N-[2-[5-(methylthio)thiophen-2-yl]-2-(oxoimino)ethyl] piperazinyl quinolone derivatives. Bioorg Med Chem 2006;14:3421–7.
   PubMed Web of Science ®Google Scholar
• Foroumadi A, Ghodsi S, Emami S, Najjari S, Samadi N, Faramarzi MA, et al. Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety. Bioorg Med Chem Lett 2006;16:3499–503.
   PubMed Web of Science ®Google Scholar
• Talath S, Gadad AK. Synthesis, antibacterial and antitubercular activities of some 7-[4-(5-amino-1,3,4 thiadiazole-2-sulfonyl)-piperazin-1-yl] fluoroquinolone derivatives. Eur J Med Chem 2006;41:918–24.
   PubMed Web of Science ®Google Scholar
• Nieto MJ, Alovero FL, Manzo RH, Maria RM. Benzenesulfonamide analogs of fluoroquinolones: antibacterial activity and QSAR studies. Eur J Med Chem 2005;40:361–9.
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Basha JS, Radhab DR, Nagaraja V. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem 2005;13:5774–8.
   PubMed Web of Science ®Google Scholar
• Kerns RJ, Rybak MJ, Glenn WK, Vaka F, Cha R, Grucz RG, et al. Piperazinyl-linked fluoroquinolone dimmers possessing potent antibacterial activity against drug resistant strains of Staphylococcus aureus. Bioorg Med Chem Lett 2003;13:1745–9.
   PubMed Web of Science ®Google Scholar
• Imramovsky A, Polanc S, Vinsova J, Kocevar M, Jampilek J, Reckova Z, et al. A new modification of antitubercular active molecules. Bioorg Med Chem 2007;15:2551–9.
   PubMed Web of Science ®Google Scholar
• Srivastava BK, Solanki M, Mishra B, Soni R, Jayadev S, Valani D, et al. Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. Bioorg Med Chem Lett 2007;17:1924–9.
   PubMed Web of Science ®Google Scholar
• German N, Wei P, Kaatz GW, Kerns RJ. Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pump. Eur J Med Chem 2008;43:2453–63.
   PubMed Web of Science ®Google Scholar
• Al-Soud Y, Al-Masoudi NA. A new class of dihaloquinolones bearing N-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and α-amino ester precursors: synthesis and antimicrobial activity. J Braz Chem Soc 2003;14:790–6.
   Web of Science ®Google Scholar
• Zhao YL, Chen YL, Sheu JY, Chen IL, Wang TC, Tzeng CC. Synthesis and antimycobacterial evaluation of certain fluoroquinolone derivatives. Bioorg Med Chem 2005;13:3921–6.
   PubMed Web of Science ®Google Scholar
• Yadav P, Joshi YC. Synthesis and spectral studies of novel ciprofloxacin derivatives. Bull Chem Soc Ethiop 2008;22:459–64.
   Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Senchani G, Banerjee D. Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg Med Chem Lett 2007;17:2372–5.
   PubMed Web of Science ®Google Scholar
• Ye FQ, Ding YM, Chen L, Ye S, Chen ZX. Synthesis and antibacterial activity of ciprofloxacin derivatives. Acta Pharmaceutica Sinica 2005;40:132–135.
   PubMedGoogle Scholar
• Bani ZT, Kujund N, Kraja MB, Njevac AV, Prodi BK. Molecular structures of new ciprofloxacin derivatives. Journal of Molecular Structure 2002;611:73–81.
   Web of Science ®Google Scholar
• Hu GQ, Wu XK, Wang X, Zhang ZQ, Xie SQ, Huang WL, Zhang HB. Synthesis and antitumor activity of C-3 heterocyclic-substituted fluoroquinolone derivatives (I): ciprofloxacin aminothiodiazole schiff-bases. Acta Pharmaceut Sin 2008;43:1112–15.
   PubMedGoogle Scholar
• Vazquez JL, Merino S, Domenech O, Berlanga M, Vinas M, Montero MT, et al. Determination of the partition coefficients of a homologous series of ciprofloxacin: influence of the N-4 piperazinyl alkylation on the antimicrobial activity. Int J Pharm 2001;220:53–62.
   PubMed Web of Science ®Google Scholar
• Azema J, Guidetti B, Dewelle J, Le Calve B, Mijatovic T, Korolyov A, et al. 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem 2009;17:5396–407.
   PubMed Web of Science ®Google Scholar
• Siddiqui R, Najma S, Khalid MK, Nosheen A, Muhammad A, Saeed A. Effects of skeletal modifications of ciprofloxacin on antibacterial, antifungal and cytotoxic activities. J Chin Clin Med 2007;2:188–95.
   Google Scholar
• Sharma PC, Jain S. Synthesis and antibacterial activity of certain novel 1-cyclopropyl-6-fluoro-1,4-dihydro-7-4-substituted-piperazin-1-yl-4-oxoquinoline-3-carboxylates. Acta Pharm Sci 2008;50:35–40.
   Google Scholar
• Hirai K, Aoyama H, Irikura T, Iyobe S, Mitsuhashi S. Differences in susceptibility to quinolones of outer mermbrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother 1986;29:535–8.
   PubMed Web of Science ®Google Scholar
• Melo MJP, Varanda FR, Dohrn R, Marrucho IM. Solubility of ciprofloxacin and moxifloxacin in different solvents: the effect of the HCl group. Enpromer 2005;1–5. http://www.enpromer2005.eq.ufrj.br/nukleo/pdfs/0984_solubility_of_antibiotics.pdf. Accessed 26 June 2009.
   Google Scholar
• Varanda F, De Melo MJP, Caco AI, Dohrn R, Makrydaki FA, Voutsas E, et al. Solubility of antibiotics in different solvents. 1. Hydrochloride forms of tetracycline, moxifloxacin, and ciprofloxacin. Ind Eng Chem Res 2006;45:6368–74.
   Web of Science ®Google Scholar
• Lavda M, Clausnitzer CE, Walters JD. Distribution of systemic ciprofloxacin and doxycycline to gingival and gingival crevicular fluid. J Periodontol 2004;75:1663–7.
   PubMed Web of Science ®Google Scholar
• Tyczkowska K, Hedeen KM, Aucoin DP, Aronson AL. High-performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue. J Chromatogr 1989;493:337–46.
   PubMed Web of Science ®Google Scholar
• Samanidou VF, Demetriou CE, Papadoyannis IN. Direct determination of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin, in pharmaceuticals and blood serum by HPLC. Anal Bioanal Chem 2003;375:623–9.
   PubMed Web of Science ®Google Scholar
• Pham HH, Luo P, Genin F, Dash AK. Synthesis and characterization of hydroxyapatite-ciprofloxacin delivery systems by precipitation and spray drying technique. AAPS PharmSciTech 2002;3:1–9.
   Google Scholar
• Krzek J, Hubicka U, Szczepaniczyk J. High-performance thin-layer chromatography with densitometry for the determination of ciprofloxacin and impurities in drugs. J AOAC Int 2005;88:1530–6.
   PubMed Web of Science ®Google Scholar
• Han-Wen S, Li-Qing L, Xue-Yan C, Hong-Mei S, Yun-Kai L. Determination of norfloxacin by flow injection analysis with chemiluminescence detection. Can J Anal Sci Spectrosc 2006;51:100–7.
   Google Scholar
• Duan J, Yuan Z. Development of an indirect competitive ELISA for ciprofloxacin residues in food animal edible tissues. J Agric Food Chem 2001;49:1087–9.
   PubMed Web of Science ®Google Scholar
• Heinz-Georg W, Stadler M, Hans-Volker T, Dalhoff A, Karl W. Degradation of ciprofloxacin by basidiomycetes and identification of metabolites generated by the brown rot fungus Gloeophyllum striatum. Appl Environ Microbiol 1999;65:1556–63.
   PubMed Web of Science ®Google Scholar
• Yan H, Tian M, Row KH. Determination of enrofloxacin and ciprofloxacin in milk using molecularly imprinted solid-phase extraction. J Sep Sci 2008;31:3015–20.
   PubMed Web of Science ®Google Scholar
• Michalska K, Pajchel G, Tyski S. Determination of ciprofloxacin and its impurities by capillary zone electrophoresis. J Chromatogr A 2004;1051:267–72.
   PubMed Web of Science ®Google Scholar
• Kassab NM, Singh AK, Kedor-Hackmam ERM, Santoro MIRM. Quantitative determination of ciprofloxacin and norfloxacin in pharmaceutical preparations by high performance liquid chromatography. Braz J Pharm Sci 2005;41:507–13.
   Google Scholar
• Xiao JB, Yang CS, Ren FL, Jiang XY, Xu M. Rapid determination of ciprofloxacin lactate in drugs by the Rayleigh light scattering technique. Meas Sci Technol 2007;18:859–66.
   Web of Science ®Google Scholar
• Ovando HG, Gorla1 N, Weyers A, Ugnia L, Magnoli A. Simultaneous quantification of ciprofloxacin, enrofloxacin and balofloxacin in broiler chicken muscle. Arch Med Vet 2004;1:93–8.
   Google Scholar
• Joos B, Ledergerber B, Flepp M, Bettex JD, Luthy R, Siegenthaler W. Comparision of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother 1985;27:353–6.
   PubMed Web of Science ®Google Scholar
• Nix DE, De Vito JM, Schentag JJ. Liquid-chromatographic determination of ciprofloxacin in serum and urine. Clin Chem 1985;31:684–6.
   PubMed Web of Science ®Google Scholar
• Martin BS, Cornejo J, Iraguen D, Hidalgo H, Anadon A. Depletion study of enrofloxacin and its metabolite ciprofloxacin in edible tissues and feathers of white leghorn hens by liquid chromatography coupled with tandem mass spectrometry. J Food Protect 2007;70:1952–7.
   PubMed Web of Science ®Google Scholar
• Egle JL. Principles of Pharmacology: Basic Concepts and Clinical Applications. New York: Chapman & Hall, 1996:1339–50.
   Google Scholar
• Leone M, Sampol-Manos E, Santelli D, Grabowski S, Alliez B, Durand A, et al. Brain tissue penetration of ciprofloxacin following a single intravenous dose. J Antimicrob Chemother 2002;50:607–9.
   PubMed Web of Science ®Google Scholar
• Lipman J, Allworth A, Wallis SC. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000;31:1131–3.
   PubMed Web of Science ®Google Scholar
• Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999;21:3–39.
   PubMed Web of Science ®Google Scholar
• Brunton LL, Lazo JS, Parker KL. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006:1111–26.
   Google Scholar
• Sharma PC, Saneja A, Jain S. Norfloxacin: a therapeutic review. Int J Chem Sci 2008;6:1702–13.
   Google Scholar
• Cheng D, Xu WR, Liu CX. Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials. World J Gastroenterol 2007;13:2496–503.
   PubMed Web of Science ®Google Scholar
• Scholar EM. Fluoroquinolones: past, present and future of a novel group of antibacterials. Am J Pharm Educ 2003;66:164–72.
   Web of Science ®Google Scholar
• Polachek H, Holcberg G, Sapir G, Tsadkin-Tamir M, Polachek J, Katz M, et al. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro. Eur J Obstet Gynecol Reprod Biol 2005;122:61–5.
   PubMed Web of Science ®Google Scholar
• Brunner M, Stab H, Moller JG, Schrolnberger C, Erovic B, Hollenstein U, et al. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 2002;46:3724–30.
   PubMed Web of Science ®Google Scholar
• Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 1991;10:267–74.
   PubMed Web of Science ®Google Scholar
• Apley MD, Upson DW. Lung tissue concentrations and plasma pharmacokinetics of danofloxacin in calves with acute pneumonia. Am J Vet Res 1993;54:937–43.
   PubMed Web of Science ®Google Scholar
• Sarkozy G. Quinolones: a class of antimicrobial agents. Vet Med Czech 2001;46:257–74.
   Web of Science ®Google Scholar
• Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310–13.
   PubMed Web of Science ®Google Scholar
• Chen DK, McGeer A, De Azaevedo JC, Low DE. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;341:233–9.
   PubMed Web of Science ®Google Scholar
• Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Chey NK, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG–TAT for drug delivery across the blood–brain barrier. Biomaterials 2008;29:1509–17.
   PubMed Web of Science ®Google Scholar
• Brook I. The prophylaxis and treatment of anthrax. J Antimicrob Agents 2002;20:320–5.
   PubMed Web of Science ®Google Scholar
• Kepa L, Oczko-Grzesik B, Stolarz W, Sobala SB. Drug-induced aseptic meningitis in suspected central nervous system infections. J Clin Neurosci 2005;12:562–4.
   PubMed Web of Science ®Google Scholar
• Mao Z, Ma L, Gao C, Shen J. Preformed microcapsules for loading and sustained release of ciprofloxacin hydrochloride. J Control Release 2005;104:193–202.
   PubMed Web of Science ®Google Scholar
• Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002;65:455–64.
   PubMed Web of Science ®Google Scholar
• Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy are fluoroquinolones still effective prophylaxis. J Urol 2008;179:952–5; discussion 955.
   PubMed Web of Science ®Google Scholar
• Gottberg AV, Klugman KP, Cohen C, Wolter N, De Gouveia L, Du Plessi M, et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008;371:1108–13.
   PubMed Web of Science ®Google Scholar
• Dollery C. Therapeutic Drugs. Edinburgh: Churchill Livingstone, 1999:N137–40.
   Google Scholar
• Efthymiopoulos C, Blum B, Maroli A, Bramer SL. Theophylline and warfarin interaction studies with grepafloxacin. Clin Pharmacokinet 1997;33:39–46.
   PubMed Web of Science ®Google Scholar
• Neu HC, Kumada T, Chin NX, Mandell W. The post-antimicrobial suppressive effect of quinolone agents. Drugs Exp Clin Res 1987;13:63–7.
   PubMedGoogle Scholar
• Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600–3.
   PubMed Web of Science ®Google Scholar
• Boy D, Well M, Kinzig SM, Sorgel F, Ankel FD, Naber KG. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004;23:6–16.
   PubMed Web of Science ®Google Scholar
• Drug card for ciprofloxacin (DB00537). Drug bank 19 Feb 2009. http://www.drugbank.ca/drugs/DB00537. Accessed 6 May 2009.
   Google Scholar
• Karachalios GN, Zografos G, Patrikakos V, Nassopoulou D, Kehagioglou K. Biliary tract infections treated with ciprofloxacin. Infection 2005;21:262–4.
   Web of Science ®Google Scholar
• Launay E, Joram N, Jacqueline C, Miegeville AF, Caillon J, Potel G, et al. Efficacy of ciprofloxacin in an experimental model of Escherichia coli chorioamnionitis in rabbits. Antimicrob Agents Chemother 2009;53:1624–7.
   PubMed Web of Science ®Google Scholar
• Capoor MR, Rawat D, Nair D, Hasan AS, Deb M, Aggarwal P, et al. In-vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant Salmonella causing enteric fever. J Med Microb 2007;56:1490–4.
   PubMed Web of Science ®Google Scholar
• Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob Agents Chemother 1998;42:984–6.
   PubMed Web of Science ®Google Scholar
• Raina R, Prawez S, Dimitrova DJ, Pankaj NK, Verma PK. Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. J Vet Sci 2008;9:241–5.
   PubMed Web of Science ®Google Scholar
• Fontan MP, Rosales M, Fernandez F, Moncalian J, Fernandez CR, Alonso A, et al. Ciprofloxacin in the treatment of Gram positive bacterial peritonitis in patients undergoing CAPD. Perit Dial Int 1991;11:233–6.
   PubMed Web of Science ®Google Scholar
• Zeiler HJ, Grohe K. The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol 1984;3:393–43.
   Google Scholar
• Vali A, Faghihi G, Zaghian N, Koosha M. The efficacy of topical solution of 0.3% ciprofloxacin in treatment of mild to moderate acne vulgaris. Iranian Red Cresc Med J 2009;11:23–27.
   Web of Science ®Google Scholar
• Bakker-Woudenberg IAJM, Ten Kate MT, Guo L, Working P, Mouyon JW. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 2001;45:1487–92.
   PubMed Web of Science ®Google Scholar
• Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. J Microbiol Immunol Infect 2001;34:178–84.
   PubMedGoogle Scholar